2 not yet recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Heart Failure, Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure, Preserved Ejection Fraction trials Research Report on Heart Failure, Preserved Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bimagrumab in Participants With HFpEF Bimagrumab, Placebo - Heart Failure, Diastolic, Diastolic Heart Failure | Phase 2 | Not yet recruiting | Eli Lilly and Company | 540 | 2026-11-01 | 2026-11-06 |
| Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF Henggliflozin Combined with Probiotics, Henggliflozin, double placebo - Heart Failure, Preserved Ejection Fraction | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital of Air Force Medicial University | 162 | 2026-07-01 | 2026-07-07 |
Heart Failure, Diastolic (2) · Sarcopenia (1)
Cardiovascular Diseases (2) · Heart Diseases (2) · Heart Failure (2) · Atrophy (1) · Muscular Atrophy (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Neuromuscular Manifestations (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Probiotics (1) · bimagrumab (1)
Eli Lilly and Company (1) · The First Affiliated Hospital of Air Force Medicial University (1)
China (1) · Hungary (1) · Italy (1) · Poland (1) · United States (1)